卷积神经网络-自我注意机制增强近红外:阿尔茨海默病与血管痴呆症的非侵入性突破
Meiyuan Chen1, Mengjiao Xue1, Yuanpeng Li1
1College of Physical Science and Technology, Guangxi Normal University & University Engineering Research Center of Advanced Functional Materials and Intelligent Sensing, Guangxi, Guilin, Guangxi, China.
Journal of biophotonics
|November 6, 2025
概括
使用近红外光谱和人工智能的新方法准确地区分了阿尔茨海默病 (AD) 和血管痴呆症 (VaD). 这种非侵入性技术实现了99.3%的准确性,为痴呆症提供了更快的诊断工具.
科学领域:
- 生物医学工程 生物医学工程
- 医学诊断 医学诊断 医学诊断
- 人工智能在医学中的应用
背景情况:
- 阿尔茨海默病 (AD) 和血管痴呆症 (VaD) 是认知能力下降的主要原因.
- 由于症状重叠和诊断标记有限,AD和VaD之间的临床区分往往很困难.
研究的目的:
- 开发和验证一种新的,非侵入性诊断方法,以区分阿尔茨海默病和血管痴呆症.
- 利用近红外光谱学 (NIRS) 与先进的机器学习相结合,以提高诊断准确度.
主要方法:
- 开发一个具有自我注意机制的卷积神经网络 (CNN-SAM) 模型.
- 将NIRS数据与用于光谱特征分析的CNN-SAM模型集成.
- 优化数据预处理,特征提取和模型参数以提高性能.
主要成果:
- 开发的CNN-SAM模型实现了99.3%的诊断准确度,以区分AD和VaD.
- 自注意力机制识别了特定的光谱频段 (1364和1484纳米),对于差异化至关重要.
- 通过严格的数据预处理和参数优化,性能得到了显著提高.
结论:
- 基于NIRS的CNN-SAM方法提供了一种快速,非侵入性和高度准确的方法来诊断AD和VaD.
- 这种人工智能驱动的诊断工具有可能在痴呆症护理中显著推进临床实践.
- 确定关键的光谱生物标志物为区分AD和VaD的潜在病理生理学提供了新的见解.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782


